Outlook Therapeutics (OTLK) Share-based Compensation (2015 - 2026)
Outlook Therapeutics (OTLK) reported Share-based Compensation of $757483.0 for Q1 2026, down 55.54% year-over-year from $1.7 million in Q1 2025, and down 14.03% quarter-over-quarter from $881150.0 in Q4 2025.
Outlook Therapeutics (OTLK) Share-based Compensation (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Share-based Compensation data on file, last reported at $757483.0 in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $757483.0, down 55.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 million (down 37.74% YoY), and the FY2025 annual result was $8.9 million, up 64.53% from the prior year.
- Share-based Compensation fell to $757483.0 in Q1 2026 per OTLK's latest filing, from $881150.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.8 million in Q1 2022 and troughed at $757483.0 in Q1 2026.
- A 5-year average of $1.6 million and a median of $1.4 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 233.07% in 2022, then sank 76.01% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $1.4 million in 2022, then decreased by 8.6% to $1.3 million in 2023, then surged by 188.57% to $3.7 million in 2024, then slumped by 76.01% to $881150.0 in 2025, then retreated by 14.03% to $757483.0 in 2026.
- Business Quant data shows OTLK's Share-based Compensation at $757483.0 in Q1 2026, $881150.0 in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | 757,483.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 757,483.00 |
| Mar 31, 2026 | 757,483.00 |
| Dec 31, 2025 | 881,150.00 |
| Dec 31, 2025 | 881,150.00 |
| Sep 30, 2025 | 1.78 Mn |
| Sep 30, 2025 | 1.78 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.27 Mn |
| Dec 31, 2023 | 1.27 Mn |